Pilot study to evaluate the safety and feasibility of intracoronary CD133+ and CD133− CD34+ cell therapy in patients with nonviable anterior myocardial infarction

Manginas, Athanassios; Goussetis, Evgenios; Koutelou, Maria; Karatasakis, George; Peristeri, Ioulia; Theodorakos, A.; Leontiadis, Evangelos; Plessas, Nikolaos; Theodosaki, Maria; Graphakos, Stelios; Cokkinos, Dennis V.

doi:10.1002/ccd.21023

Cited by 73 publications

(46 citation statements)

References 40 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Particularly autologous CD34 ϩ or CD133 ϩ stem/ progenitor cells have been therapeutically transplanted in patients with severe ischemic heart or limb diseases, and these initial clinical experiences indicate the safety and feasibility as well as the effectiveness of cell-based therapy [3,[11][12][13][14][15][16][17][18][19].…”

Section: Several Translational Researchers Have Demonstrated That Cd34mentioning

confidence: 99%

Development of Serum-Free Quality and Quantity Control Culture of Colony-Forming Endothelial Progenitor Cell for Vasculogenesis

Masuda

Iwasaki

Kawamoto

et al. 2012

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Quantitative and qualitative impairment of endothelial progenitor cells (EPCs) limits the efficacy of autologous cell therapy in patients with cardiovascular diseases. Here, we developed a serum-free quality and quantity control culture system for colony-forming EPCs to enhance their regenerative potential. A culture with serum-free medium containing stem cell factor, thrombopoietin, vascular endothelial growth factor, interleukin-6, and Flt-3 ligand was determined as optimal quality and quantity culture ( MEDICINE 2012;1:160 -171

show abstract

Section: Several Translational Researchers Have Demonstrated That Cd34mentioning

confidence: 99%

Development of Serum-Free Quality and Quantity Control Culture of Colony-Forming Endothelial Progenitor Cell for Vasculogenesis

Masuda

Iwasaki

Kawamoto

et al. 2012

Stem Cells Translational Medicine

View full text Add to dashboard Cite

show abstract

“…When comparing the DanCell study to other studies similar in design and demographics, no significant increase in LVEF was found in DanCell, while other studies have been able to show this [4,7,8,9,10,11]. In DanCell, the evaluation of LVEF was performed in a blinded setting, thus excluding bias.…”

Section: Discussionmentioning

confidence: 99%

“…In the two randomized controlled trials using intramyocardial injection of stem cells, improvement in LVEF was shown [7,11] and one showed improvement in mortality [7]. The rest of the comparable studies all used intracoronary administration, and these also seem to have a positive outcome [4,8,9,10]. On the basis of the current limited data, a recent meta-analysis found that intramyocardial injection may be superior to intracoronary infusion in patients with LV systolic dysfunction [3].…”

Section: Discussionmentioning

confidence: 99%

Intracoronary Injection of CD34+-Cells in Chronic Ischemic Heart Failure: 7 Years Follow-Up of the DanCell Study

et al. 2014

View full text Add to dashboard Cite

Objectives: Seven years ago, the DanCell study was carried out to test the hypothesis of improvement in left ventricular ejection fraction (LVEF) following repeated intracoronary injections of autologous bone marrow-derived stem cells (BMSCs) in patients suffering from chronic ischemic heart failure. In this post hoc analysis, the long-term effect of therapy is assessed. Methods: 32 patients [mean age 61 (SD ± 9), 81% males] with systolic dysfunction (LVEF 33 ± 9%) received two repeated intracoronary infusions (4 months apart) of autologous BMSCs (1,533 ± 765 × 10⁶ BMSCs including 23 ± 11 × 10⁶ CD34⁺ cells and 14 ± 7 × 10⁶ CD133⁺ cells). Patients were followed for 7 years and deaths were recorded. Results: During follow-up, 10 patients died (31%). In univariate regression analysis, the total number of BMSCs, CD34⁺ cell count and CD133⁺ cell count did not significantly correlate with survival (hazard ratio: 0.999, 95% CI: 0.998-1.000, p = 0.24; hazard ratio: 0.94, 95% CI: 0.88-1.01, p = 0.10, and hazard ratio: 0.96, 95% CI: 0.87-1.07, p = 0.47, respectively). After adjustment for baseline variables in multivariate regression analysis, the CD34⁺ cell count was significantly associated with survival (hazard ratio: 0.90, 95% CI: 0.82-1.00, p = 0.04). Conclusions: Intracoronary injections of a high number of CD34⁺ cells may have a beneficial effect on chronic ischemic heart failure in terms of long-term survival.

show abstract

“…9 Another study indicated that early intracoronary administration of haematopoietic BMMCs in patients with previous myocardial infarction was associated with accelerated luminal loss and reduced conductance of the infarct-related artery. 18 Manginas et al 19 …”

Section: Safetymentioning

confidence: 99%

Stem Cell Transplantation in Cardiovascular Disease: An Update

et al. 2012

View full text Add to dashboard Cite

Despite the development of novel therapeutic strategies, cardiovascular diseases remain the main cause of morbidity and mortality worldwide. Many phase 1 and 2 clinical trials have reported the safety, feasibility and promising potential of stem cell transplantation, however, the optimal cell types, timing of infusion, cell dosage and routes of administration remain to be determined. This paper reviews the findings of various clinical studies and discusses the challenges facing the delivery of stem cell therapy in cardiovascular diseases.

show abstract

Pilot study to evaluate the safety and feasibility of intracoronary CD133⁺ and CD133⁻ CD34⁺ cell therapy in patients with nonviable anterior myocardial infarction

Abstract: Intracoronary infusion of selected CD133(+) and CD133(-)CD34(+) progenitor cells to a previously infarcted and nonviable anterior wall is safe, and results in sustained improvement in segmental myocardial perfusion and in favorable left ventricular remodeling.

Cited by 73 publications

References 40 publications

Development of Serum-Free Quality and Quantity Control Culture of Colony-Forming Endothelial Progenitor Cell for Vasculogenesis

Development of Serum-Free Quality and Quantity Control Culture of Colony-Forming Endothelial Progenitor Cell for Vasculogenesis

Intracoronary Injection of CD34+-Cells in Chronic Ischemic Heart Failure: 7 Years Follow-Up of the DanCell Study

Stem Cell Transplantation in Cardiovascular Disease: An Update

Contact Info

Product

Resources

About